Prostate Cancer Coverage from Every Angle

Capivasertib Plus Chemotherapy in Metastatic Castration-Resistant Prostate Cancer

By: Kayci Reyer
Posted: Wednesday, April 14, 2021

Research from the phase II ProCAID trial, published in the Journal of Clinical Oncology, found that adding capivasertib, a pan-AKT inhibitor, to docetaxel-based chemotherapy did not result in improved composite progression-free survival in patients with metastatic castration-resistant prostate cancer. Docetaxel resistance frequently occurs during or shortly after treatment concludes.

“Intriguingly, however, we have detected a substantial increase in the [overall survival] secondary endpoint,” noted Robert J. Jones, PhD, of Beatson West of Scotland Cancer Centre in Glasgow, and colleagues. “Data from this study do not provide a definitive explanation for why the addition of capivasertib to chemotherapy might extend [overall survival] but not [progression-free survival].

The study included 150 patients who received a maximum of 10 21-day cycles of intravenous docetaxel and oral prednisolone. In addition, participants were randomly assigned to receive either oral capivasertib or placebo until disease progression. Composite progression-free survival was determined and included prostate-specific antigen suppression events.

Among patients receiving capivasertib, the median composite progression-free survival was 7.0 months (95% confidence interval [CI] = 6.3–8.3 months), and the median overall survival was 31.2 months (95% CI = 20.1 months to not reached). In the placebo group, the median composite progression-free survival was 6.7 months (95% CI = 5.5–7.4), and the median overall survival was 20.3 months (95% CI = 17.5–24.2 months).

A patient’s P13K/AKT/PTEN pathway activation status did not appear to affect composite progression-free survival or overall survival outcomes for either group. The groups both experienced a grade 3 to 4 adverse event rate of 62.2%. Diarrhea, fatigue, nausea, and rash were the most commonly reported adverse events related to capivasertib treatment.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.